Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Dong-Churl Suh & Mark Aagren. (2011) Cost–effectiveness of insulin detemir: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 11:6, pages 641-655.
Read now
Read now
Phil McEwan, Chris D. Poole, Tony Tetlow, Paul Holmes & Craig J. Currie. (2007) Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Current Medical Research and Opinion 23:sup1, pages S21-S31.
Read now
Read now
Simon Dixon & John R. Peters. (2007) Evaluating the ‘real’ cost-effectiveness of health technology: reconciling the public interest with patients’ interests. Current Medical Research and Opinion 23:sup1, pages S1-S6.
Read now
Read now
Craig J. Currie, Chris D. Poole, Tony Tetlow, Paul Holmes & Phil McEwan. (2007) The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Current Medical Research and Opinion 23:sup1, pages S33-S39.
Read now
Read now
Articles from other publishers (18)
Kirsty Winkley, Rebecca Upsher, Daniel Stahl, Daniel Pollard, Architaa Kasera, Alan Brennan, Simon Heller & Khalida Ismail. (2020) Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review. Health Technology Assessment 24:28, pages 1-232.
Crossref
Crossref
Daniel B. Horton, Harshvinder Bhullar, Lucy Carty, Francesca Cunningham, Alexis Ogdie, Janet Sultana & Gianluca Trifirò. 2019. Pharmacoepidemiology. Pharmacoepidemiology
241
289
.
Alison J Dunkley, Freya Tyrer, Rebecca Spong, Laura J Gray, Mike Gillett, Yvonne Doherty, Lorraine Martin-Stacey, Naina Patel, Thomas Yates, Sabyasachi Bhaumik, Thomas Chalk, Yogini Chudasama, Chloe Thomas, Susannah Sadler, Sally-Ann Cooper, Satheesh K Gangadharan, Melanie J Davies & Kamlesh Khunti. (2017) Screening for glucose intolerance and development of a lifestyle education programme for prevention of type 2 diabetes in a population with intellectual disabilities: the STOP Diabetes research project. Programme Grants for Applied Research 5:11, pages 1-316.
Crossref
Crossref
Joaquín E. Caporale, Andrés Pichón-Riviere, Andrea G. Beratarrechea, Cristian Von Schulz-Hausmann & Federico Augustovski. (2014) A Comparison of 1-Year Treatment Costs in Patients with Type 2 Diabetes Following Initiation of Insulin Glargine or Insulin Detemir in Argentina. Value in Health Regional Issues 5, pages 14-19.
Crossref
Crossref
Jen Kruger & Alan Brennan. (2012) The cost of Type 1 diabetes mellitus in the United Kingdom: a review of cost-of-illness studies. The European Journal of Health Economics 14:6, pages 887-899.
Crossref
Crossref
Alexis Ogdie, Sinéad M. Langan, John Parkinson, Hassy Dattani, Karel Kostev & Joel M. Gelfand. 2012. Pharmacoepidemiology. Pharmacoepidemiology
224
243
.
F. ?lvarez Guisasola, D. Mauricio Puente, T. Garc?a Coscol?n, L. Beteg?n Nicol?s & C. Rubio-Terr?s. (2010) An?lisis de costes del tratamiento de la diabetes mellitus tipo 2 con insulina glargina o detemir. Avances en Diabetolog?a 26:6, pages 430-435.
Crossref
Crossref
Marc L Evans, Peter Sharplin, David R Owens, George H Chamberlain, Andrea J Longman & Philip McEwan. (2010) Insulin usage in type 2 diabetes mellitus patients in UK clinical practice: a retrospective cohort-based analysis using the THIN database. The British Journal of Diabetes & Vascular Disease 10:4, pages 178-182.
Crossref
Crossref
Peter Sharplin, Jason Gordon, John R Peters, Anthony P Tetlow, Andrea J Longman & Philip McEwan. (2009) Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary care-based analysis. Cardiovascular Diabetology 8:1.
Crossref
Crossref
Peter Sharplin, Jason Gordon, John R Peters, Anthony P Tetlow, Andrea J Longman & Philip McEwan. (2009) Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study. Cardiovascular Diabetology 8:1.
Crossref
Crossref
C. J. Currie. (2009) The longest ever randomised controlled trial of insulin glargine: study design and HbA1c findings. Diabetologia 52:10, pages 2234-2235.
Crossref
Crossref
Christopher K. Johnson & Mona Shimshi. (2009) When a unit of insulin is not a unit: Detemir dosing and insulin cost in type 2 diabetes mellitus. Insulin 4:2, pages 87-93.
Crossref
Crossref
Julia M. Bottomley & Frank D. Raymond. (2009) Pharmaco-economic issues for diabetes therapy. Insulin 4:1, pages 32-60.
Crossref
Crossref
Andrew Maguire, Betina T. Blak & Mary Thompson. (2008) The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiology and Drug Safety 18:1, pages 76-83.
Crossref
Crossref
. (2008) Current World Literature. Current Opinion in Endocrinology, Diabetes & Obesity 15:4, pages 383-400.
Crossref
Crossref
C. J. Currie, M. Evans & C. D. Poole. (2007) Letter. Diabetes, Obesity and Metabolism 10:1, pages 94-95.
Crossref
Crossref
Julia M. Bottomley & Frank D. Raymond. (2007) Pharmaco-economic issues for diabetes therapy. Best Practice & Research Clinical Endocrinology & Metabolism 21:4, pages 657-685.
Crossref
Crossref
C. J. Currie. (2007) Reliably assessing the cost-effectiveness of continuous subcutaneous insulin infusion vs. multiple daily injections in the UK: what are the issues?. Diabetic Medicine 24:10, pages 1058-1059.
Crossref
Crossref